Hello, my name is Erica, and I will be your conference operator today. At this time, I would like to welcome everyone to the Envista Holdings Corporation Q1 2020 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during that time, simply press star, then one on your telephone keypad. If you would like to withdraw your question, please press the pound key on your telephone keypad. I will now turn the call over to Mr. John Bedford, Vice President of Investor Relations. Mr. Bedford, you may begin your conference.
Hello, everyone, and thanks for joining us on the call. With us today are Amir Aghdaei, our President and Chief Executive Officer, and Howard Yu, our Chief Financial Officer. I'd like to point out that our earnings release, the slide presentation supplementing today's call, and the reconciliations and other information required by SEC Regulation G relating to any non-GAAP financial measures provided during the call, are available on the investor section of our website, www.envistaco.com. The audio portion of this call will be archived on the investor section of our website later today under the heading Events and Presentations, and will remain archived until our next quarterly call. A replay of this call will also be available. During the presentation, we will describe some of the more significant factors that impacted year-over-year performance. The supplemental materials describe additional factors that impacted year-over-year performance.
Unless otherwise noted, all references in these remarks and supplemental materials to company-specific financial matrix relate to the Q1 of 2020, and all references to period-to-period increases or decreases in financial matrix are year-over-year. We may also describe certain products and devices which have applications submitted and pending for certain regulatory approvals or are available only in certain markets. During the call, we will make forward-looking statements within the meaning of the federal securities laws, including statements regarding events or developments that we believe or anticipate will or may occur in the future. These forward-looking statements are subject to a number of risks and uncertainties, including those set forth in our SEC filings, and actual results might differ materially from any forward-looking statements that we make today.
These forward-looking statements speak only as of the date that they are made, and we do not assume any obligation to update any forward-looking statements, except as required by law. With that, I'd like to turn the call over to Amir.
Thanks, John. Welcome everyone to Envista's Q1 2020 earnings call. I hope everyone joining us today is well, safe, and healthy. For those who are affected by the global pandemic, you are in our thoughts. On behalf of Envista, I want to express our appreciation for those in the healthcare field who are working diligently around the globe to safeguard us all. This includes the many dental professionals who have worked tirelessly and selflessly to ensure patients continue to have access to care. I would like to thank our employees for their commitment, engagement in their communities, and constant focus on keeping their families, our customers, partners, and fellow employees safe. Thank you for all that you do. We're going to change the cadence of the call today, given the unique nature of these circumstances.
I will start by walking you through our approach to address COVID-19 before handing it off to Howard, who will share our quarterly results, and then I will walk you through what we are seeing in the world today and how we see Envista positioned for the new normal. When we reflect on the Q1, we feel good about the progress we made during the first two months of the year, with revenue exceeding our expectations. With the emergence of the global health pandemic, our business experienced a significant adverse impact in the last three weeks of March. This caused us to pivot our focus and adjust to new realities we face today. Our approach to the current health crisis is focused on what's important: the safety of our employees, supporting our customers, partners, and communities, and preserving our financial strength.
First and foremost, our number one priority is the health and safety of our employees. The actions to protect employees are driven by a task force that was assembled very early in the 1st quarter. This team acted quickly and efficiently to move those who can work remotely to their homes and implemented safety protocols for other employees, including social distancing measures, staggered shifts, personal protective equipment, and more frequent disinfection processes. We increased the use of virtual technology to provide the investor leadership team the ability to communicate on a regular basis with our employees and enable remote collaboration. Most importantly, we increased the frequency of cross-company communication with a weekly CEO town halls open to all 12,000 employees. In these sessions, we share our immediate actions, the strategy, and offer the opportunity to ask the leadership any question.
We have held hundreds of virtual Kaizens online training events, which provide employees the opportunity to continue learning and improving business practices. Finally, we put together a back-to-work plan to protect employees and customers as they begin returning to the office environment. These activities have prepared us to enter back to work more knowledgeable, using new tools and resources, and become more productive by utilizing virtual connectivity like never before. After employees, our focus is on supporting our customers, partners, and the communities we serve. Now more than ever, our partner and customers are looking for us to support them through this crisis. One of the ways we have supported and collaborated with them during this difficult period is by expanding the availability of remote support, virtual trainings, and education. The response from customers far exceeded our expectations.
Last month, we held the Nobel Biocare Global Symposium virtually for the first time and had a record 12,000+ clinicians register to learn from their peers about innovative implant and workflow solutions and best practices to grow their patient base. In the Q1, we substantially increased online training and education content and frequency, and had more than 200,000 participants across our operating companies. Many of these interactions resulting in new leads. This is significantly greater than any prior period and demonstrate the strength of Envista's customer education programs. We're proud of our role in protecting the health of our customers and the communities we serve around the globe. Envista employees donated thousands of masks and other personal protective equipment to their local communities worldwide.
In China, we were one of the first companies to donate infection prevention products to the Wuhan government. Our ophthalmic business donated eye protection to hundreds of healthcare professionals. Through our infection prevention business metrics, our team worked tirelessly during the crisis to ensure continuity of shipment of medical-grade disinfection products used by healthcare professionals. Financially, we are now in a changed environment that requires us to operate effectively, to preserve our strength and ensure long-term financial success. This requires an acknowledgment of the current realities we are confronting, refining priorities, accelerating our portfolio optimization, and relentless execution. Our first focus is business continuity. We tested our continuity plans and assessed our supply chain to ensure our factories can keep producing. We also increased inventory levels to ensure our businesses have the appropriate stock on hand to meet customers' needs.
We have not experienced any significant supply or manufacturing issues today and have maintained high levels of service to our customers. After securing our business, we then turned to our existing debt arrangements and renegotiated with our lenders to provide a suspension of debt leverage covenant through the Q1 of 2021. We drew $215 million on our revolver to provide additional liquidity over the coming quarters. These actions are intended to provide us flexibility in this uncertain environment. Operating in this new reality also requires us to acknowledge the need to take more aggressive actions to align our cost structure. Our approach has been to adjust in the short term to preserve capital by executing executive and management pay cuts, furloughs, and foregoing most discretionary spend and capital expenditures.
Collectively, we anticipate these actions will help reduce our operating expenses by more than $100 million, much of this in the Q2. We will modulate these actions for the balance of the year as we gain further visibility on the recovery trajectory. We are also taking additional actions to change the long-term financial structure of the business and adjust our portfolio to what will become a new normal. As you may recall, our previous structural cost reduction plan committed to $60 million in savings to be achieved over the next three years. In this new environment, we are now moving forward with an increased reduction program targeted to reduce expenses by more than $100 million on an annualized basis through EBS-driven productivity gains, a targeted reduction of more than 10% of our global workforce, and portfolio rationalization.
With regards to the portfolio rationalization, there are areas of the business that will be more impacted than others as we emerge from the existing crisis, particularly in capital-intensive areas like treatment units. For this reason, we have announced our intention to exit Pelton & Crane, and are in the process of taking additional actions to reduce our exposure to capital equipment. These businesses were approximately 4% of our 2019 revenue and operate at a break-even operating margin. We began to accelerate cost actions in the Q1 and anticipate the remaining work to be completed by the end of 2020. We are also adjusting organic growth priorities to align with increased infection prevention needs globally, while focusing on strategic areas that will enhance our competitive advantage, including the Spark clear aligners, the N1 implant system, and diagnostics and workflow software.
Given the current focus on infection prevention globally, this has quickly become an area of opportunity where we can augment growth by helping our customers and the broader healthcare community to improve quality of clinical care for their patients. Accordingly, we have increased capital investment in this area to further expand capacity, approximately 25% by end of June. The payoff of this investment is less than two months, and we will look to further expand capacity going forward. Turning to Spark, at February's Ormco Forum, current key users showcased the clinical benefits of our clear aligners to more than 750 practitioners. Many of these clinicians expressed interest in the product and signed up to participate in the next phase of the Spark expansion plan.
As we shared in the past, we anticipate Spark to be a major contributor of growth as we move through 2020 and beyond. The Nobel Biocare team made significant progress on the N1 implant system by submitting and receiving CE marking for the first portfolio launch. N1 is a patented system that support the complete implant workflow, from planning to prosthetic delivery. It includes new techniques like OsseoShaper, a treatment protocol that allows clinicians to treat patients with two easier-to-use, lower-speed instruments, which ultimately results in less discomfort for patients. The team is on track to make the product available for limited sale during the current pandemic and plans to pursue a structured phase launch during the second half of 2020. Finally, at the Chicago Dental Society Midwinter Meeting in February, we launched our flagship digital workflow product, DTX Studio Clinic in North America.
DTX is an open architecture platform that leverages imaging diagnostics tools and integrates the workflow from multiple disciplines, including implantology, oral surgery, and dental laboratories into one software system. DTX is cloud-based and particularly well-suited for DSOs and multi-office settings looking to implement a standardized workflow. While we have a clear set of priorities, we recognize what sets a high-performing organization apart is having agility, discipline, and a methodology to track progress and course-correct as needed. There will be bumps in the road ahead, and we are prepared to navigate them with our culture of continuous improvement and our EDS toolset. When we started our crisis management process early in the Q1, one of the first groups we brought in was our Envista Business System office.
As we developed our plan, this involvement helped build project management tools to structure and ramp our virtual, internal, and external training and education capabilities. Quantify and help track our cost reduction efforts around personnel actions and expense management by installing daily and weekly standard work. Likewise, we have applied the same principles to our scenario planning process, which I will go into more detail later on. We now have better visibility on a day-to-day basis of where we stand and have established a standard work to assess progress and course correct as needed in these critical priorities. The EDS mindset is one of relentless pursuit of our commitments and help us meet and exceed our expectations. I will now turn it over to Howard, who will provide further details on the quarter.
Thanks, Amir. Q1 sales declined 17.1% to $547.2 million. Sales were adversely impacted 0.9% from discontinued products and 1.8% from foreign currency. Core sales decreased 14.6%, primarily due to lower demand as a result of the global health pandemic, which we estimate impacted revenue by 16%. Through the first two months of the quarter, we achieved mid-single-digit core revenue growth and were above our forecast, including the negative impact of COVID-19 in China. Revenue declined more than 50% in the last three weeks of the quarter, ended April 3rd. Geographically, developed markets decreased at a low teens rate, led by Western Europe, which was the first major developed region impacted by the pandemic.
In North America, we saw a slowdown towards the end of the quarter as most practices in Canada were closed and many states in the US issued guidance to temporarily suspend elective procedures. We were encouraged by the continued traction made at our top 10 DSO customers, with our revenue from those customers growing at a high single-digit rate in the quarter. Emerging market sales were down approximately 20%, led by China, which declined by more than 35%. Gross margins declined 410 basis points to 50.9%, due primarily to unfavorable mix as a result of a larger decline in our higher-margin specialty businesses and increased capacity building for Spark clear aligners.
Adjusted operating profit margin decreased 840 basis points to 1.8%, largely due to the factors above and incremental public company costs, partially offset by savings from our temporary and permanent spending reduction programs. Our Q1 adjusted diluted EPS was $0.03. During the quarter, our operating cash flow was negative $62 million, and our free cash flow was negative $76 million, largely due to lower earnings, the timing of prior incentive compensation payouts, and an increase in inventory to allow factory closures and provide business continuity. We had good performance in working capital with the benefit of approximately $100 million from strong management of our collections and payables. After quarter end, we obtained an agreement from our existing lenders for the suspension of our debt leverage covenants through Q1 of 2021, among other amendments.
Our cash balance was $354 million at the end of the quarter. Obtaining the covenant waiver, combined with the cost actions and our existing cash, provides us with increased flexibility to manage the business. As Amir mentioned earlier, we are actively monitoring our positioning and will modulate both our cost programs and capital structure to ensure we maintain sufficient liquidity. Now to our two business segments. Our Specialty Products & Technologies segment sales were down 21.8%, while core revenue declined 19.4%, with the impact of COVID-19 approximately 22%. Both ortho and implant have a higher exposure to regions, including China, Italy, Spain, and France, that were more heavily impacted by the pandemic earlier in the quarter.
We are encouraged by the pro-progress the ortho team has made with their clear aligner product, Spark, which contributed approximately 50 basis points to overall growth to Envista in the Q1. In our implant business, we previously discussed making changes to the commercial organization in both North America and Europe during the fourth quarter to help improve operational effectiveness. The team has made tremendous progress with our premium implant business growing at mid-single-digit rate prior to the outbreak of COVID-19 in these geographies. The Nobel Biocare team also obtained EU Medical Device Regulation Quality Management System certification from their notified body ahead of the effective 2021 date, and is one of the first in the dental industry to do so. This is an important milestone for Nobel Biocare and shows that they are right on track to achieve MDR certification for the full portfolio of products.
This further demonstrates the commitment Nobel Biocare has to their customers and their patients to ensure that products and solutions remain available as these new regulations go into effect in 2021. Specialty Products & Technologies adjusted operating profit margins declined 8.5%, largely due to lower revenue and continued investment in strategic initiatives, including N1 implant system, which received a CE mark in Europe, and Spark, which were only partially offset by savings. In our equipment and consumables segment, core revenue decreased 9.2%, with the impact from COVID-19 approximately 10%. Despite the decline in revenue, our business is well-positioned as a result of distribution management processes we put in place over the last few years. Inventory levels at major US distributors are now at their lowest levels in recent history.
Our equipment business declined low double digits, led by mid-teens decline in treatment units, while consumables declined mid-single digits. Within consumables, our infection prevention business grew more than 35%, as demand amongst dental and medical institutions was robust. As Amir mentioned previously, we are investing in this business to increase capacity a further 25% and anticipate new production will be online by the end of June. Equipment and consumables adjusted operating profit margin increased 110 basis points to negative 0.3%, largely due to the team's continued traction on refining our portfolio and reducing structural business costs. I'll now turn it back to Amir, who will walk you through some details of the current operating environment.
Thanks, Howard. While we're not providing formal guidance, given the uncertainty created by the pandemic, we want to provide you with some additional market commentary. We'll also share the steps we're taking to assess and plan for the impact of COVID-19. We hope this will give you a better understanding of how the business will perform short term, and how we are ensuring we set our business up to thrive as we emerge from the crisis. Let me start with our experience in China. Beginning in February and continuing through early March, we saw minimal volume as the country was effectively locked down. From mid-March through the end of the quarter, we saw a modest recovery to approximately 25% of the patient volumes. By the end of April, most clinics were open, but patient volumes were just over 50% of pre-COVID-19 levels.
Over the last few weeks, we continue to see improvement in patient traffic, while our commercial teams anticipate a gradual return of volume through the remainder of the quarter. The performance we are seeing varies regionally and by country based on the infection progression and local government mandates. Asia Pacific is further along in the recovery than other regions, as they were first to experience an impact. Australia is beginning to recover, Japan offices have remained open, despite operating at a relatively low level of patient traffic. We estimate about a third of European dental offices are now open. Germany is showing encouraging signs with improving activity through the month of April, as some offices have started to restock. Similarly, many areas of Scandinavia have had much lower impact than the rest of the continent.
On the other end of the spectrum, southern European countries and France still have very little activity, as they had some of the more stringent stay-at-home orders imposed. We anticipate these will be last to recover. In the US, we are still very early in the recovery process, but are seeing encouraging signs, with the states representing more than half of the population lifting restrictions, with more set to do so in the coming days. In nearly all cases, offices open first, followed by gradual return of patient volume. In April, global sales declined more than 60% from the prior year, but importantly, we started to experience stabilization and improvement as we moved through April and into May. We anticipate a gradual recovery in business through the second half of the year. To operate in this dynamic environment, we have created a framework to provide us near-term visibility.
We're tracking office openings globally and monitoring several leading indicators, including imaging usage data, to ensure we can react quickly as clinicians come back to work. We changed the way we operate by modeling a set of scenarios to ensure we have the financial actions prepared to withstand the environment over the next several quarters. This framework informed our decision-making process with respect to our liquidity needs and our cost actions. As we move through the intermediate impact caused by office closure and a stay-at-home orders across the globe, we believe our portfolio is well positioned to navigate through a recessionary environment. Over 70% of our total business is based in consumables, including more than $150 million in our infection prevention business.
We anticipate our infection control business can influence the quality of patient care, and will be positively impacted by required changes to dental and medical office disinfection procedures. Furthermore, our position in emerging markets and innovations, including the DTX diagnostics workflow, N1 Implant System, and the Spark clear aligners, will provide sustainable competitive differentiation to accelerate growth, improve margin, and gain market share as we move forward. Approximately half of our $850 million equipment business is dental handpieces, portable X-ray equipment, and intraoral sensors that do not require third-party installation. This equipment is necessary to perform nearly any office procedure, largely driven by replacement demand, and it's generally priced under $5,000 on average, which makes it more transactional than other large capital equipment purchases.
We anticipate the remaining equipment business, composed on higher priced imaging devices and dental treatment centers, to be most impacted moving forward, as fewer new offices are built and purchases above $25,000 are postponed. As I mentioned earlier, we are exiting over 25% of this more exposed segment of our capital business. To summarize, our near-term priorities are the safety of our employees, supporting our customers, partners, and the community, and preserving our financial strength. These priorities are also aligned to our long-term goal of enhancing our growth portfolio with strategic investments, including implant, clear aligners, and emerging markets, expanding operating margin through cost reduction actions and improved business mix, and continuing to transform our portfolio to create a stronger Envista.
The ability to achieve these strategic objectives and create value is directly dependent on the strength of our employees, our relationship with our customers and partners, the Envista leadership team, and our EDS Foundation. While we have been a public company for less than nine months, our leadership has decades of industry and management tenure. We're committed to executing and managing through challenging times, and are confident in our ability to build a stronger Envista for the future.
Thanks, Amir. That concludes our formal comments. Erica, we're now ready for questions.
As a reminder, to ask a question, you will need to press star one on your telephone. To withdraw your question, press the pound key. Please stand by while we compile the Q&A roster. Your first question in queue comes from Jeff Johnson with Baird.
Thank you. Good evening, guys. Hopefully, you can hear me okay. Howard or Amir, Yeah, good evening or good afternoon. Howard, maybe starting with you, just from a balance sheet and a cash flow perspective, I was wondering if you could give us an update on your liquidity thoughts from here. Obviously, $350 million on the balance sheet. If revenues kind of continue to trend in the way you're expecting over the next three to six months, how comfortable are you with current liquidity? I know in the documents you filed yesterday, you have to keep over $125 million of liquidity each month. Do you think there will be additional capital raises or need to access additional facilities from here?
Sure, Jeff. Yeah, I mean, we feel good. The first step was getting this covenant amendment, you know, executed. With that now behind us, we continue to focus here on the actions to go ahead and save costs. We're looking at both, you know, temporary costs or, of in excess of $100 million. Much of that to come in the Q2, as well as Amir mentioned, structural changes, that would be an additional $100 million. We had talked in the past about a $60 million cost takeout over three years. We're looking to accelerate that and do a lot of those actions, by the time we exit 2020 here. We think that between that, the cash on hand, that positions us well to work our way through this environment and weather this crisis.
You know, in terms of priorities, we are focused on making sure that we have cash and liquidity throughout. You know, we're focusing also on daily management of our cash, and so that's looking at collections and payables. I mentioned earlier in our comments that we had $100 million of cash flow positive associated with the work that we've done on our collection side as well. We very much plan on continuing to do those efforts as well. In terms of liquidity and other options, certainly, we will continue to monitor that. We'll look at it. We have options such as, you know, short-term facilities, 364-day facility. We can look at convertible instruments, you know, that can even limit some of the equity dilution as well.
Clearly, you know, we value our equity interest in our stakeholders, and we'd be very conscientious about dilution as we think about our liquidity concerns going forward as well.
All right. That's helpful. Amir, maybe one just higher level question for you. You're in a unique position of having both a sizable implant and orthodontic business. We all have our opinions of what's going to come back first, second, third, in kind of the recovery phase. How are you thinking about recovery and in orthodontics, especially clear aligners versus brackets and wires? Any thoughts on how that could or could not recover over the next couple quarters, and maybe play that off relative to expectations on a dental implant recovery? Thank you.
Thank you, Jeff. Thank you for your weekly survey. That has been really helpful to get your perspective on the market. As you can imagine, there are a lot of unknowns at this point, but we do believe that consumable will come back, and specialty business will come back first, equipment next, and due purely because of the higher capital demand. That's why we took the action item to divest and, I'm sorry, to shut down some of our treatment centers. On modeling and expectation are gradual increases in May and June as offices start opening by geography. The speed of recovery, to a large degree, has to do with the government guidelines and practices on reopening. We think the consumer confidence macro factors play an important perspective.
From a procedure perspective, we think ortho and endo, purely because of the emergency nature of it, are going to come back first. This will be likely followed by procedures that require lower speed handpieces. We're monitoring several factors, you know, disease progression, office opening, consumer confidence. We are interviewing hundreds of dentists, talking to DSOs and others. We are looking at information on imaging devices, and through our interviews, we have the feeling that we have a really good handle on what is taking place in here. We have started seeing some of the stock requests coming back, not only in the US, but also in Australia, New Zealand, and some cases from the European are beginning to come in. It's given us the confidence that we can start ramping some of our production capabilities moving forward.
We're monitoring that on a daily and weekly basis and adjusting as we go forward.
Thank you, Jeff. Next question, operator.
Our next question is from Tycho Peterson with JP Morgan.
Hey, thanks. Amir, you know, given the China example, can you just talk if there are, you know, structural differences between, you know, the China market, US, EU, that would make the recovery there more or less relevant? How do you think about the lag between dental offices here reopening and the resumption of purchases? You mentioned infection prevention as a tailwind. Can you maybe just talk a little bit about how you think about that opportunity?
Of course. Thank you, Tycho. It is not necessarily a perfect match and a read-through to other geographies, given that there's much more government control. We think individuals, it's a good indicator of the gradual recovery. In China, we started off really strong in January, and the results were better than expected. From Lunar New Year to early March, virtually, there were no office activities. We saw a gradual improvement in patient volume once the offices opened. From end of March, the three weeks in March, we saw a steady recovery to about 15%-25% activities. At the end of April, we have seen about recovery to almost about 50%, and it is improving.
As I said before, ortho, emergency cases, general hygiene, cleaning, were first to recover, but some other procedures are purely driven by government standards and guidance. We use China as a good proxy, but we are trying to understand the limitation that China has had in order to replicate that in other developed markets. Our hygiene business, infection prevention business, has been a really important factor in here. We donated to the Wuhan government and have been able to put a series of recovery, go back to work program on how to disinfect offices. We have had significant ramp and walked away at the end of Q1 with some pass-through in order to really expand this business. In order to look at geographies, we normally look at three different segment. 15% of our business is in APAC, in Japan, China, Australia, and New Zealand.
I think majority of those offices are open now. The next group are DACH and Nordic, about 10% of our business in those geographies, and the remaining 75% in North America, Western Europe, and rest of the world. China and APAC are further along on the recovery curve, and we have seen significant impact and recovering very quickly. DACH and Nordic is starting to see some recovery. Major offices are beginning to open now. In category three, that North America, Western Europe, are largely under lockdown till April, but seeing some encouraging sign. As I said, in April, we saw a 60% decline, but we think that was the bottom, and from then on, we are beginning to see a step-by-step improvement by geography.
If I could ask one follow-up on implant, it's early days for N1, but, you know, does the current environment change your view on value versus premium? You know, if we're in a recessionary environment, does the mix shift skew more toward value, and does that change your, the outlook for N1 at all?
Well, we are excited about the approval that we got. This was a major milestone, and to be honest, it was ahead of what we had anticipated. We'd be thoughtful on, during pandemic, to make sure that we are onboarding correctly. We saw a really good program with a Spark onboarding. We want to do the same thing in here to get infrastructure built, to make sure an end-to-end solution is provided, to make sure that first group are truly successful before we create the next phase as we go forward. I think the largest problem for patient and doctor for implant procedures are fear, procedure time, total treatment time, and N1 improves all of this. It's easier to use clinically, specifically for DSOs, two versus four or five drills, easier to train new dentists. It covers all indication.
In Europe, as we talked about, we intend to start, and this may be as early as June, we start expanding that and growing that over time. We haven't seen any specific information that says value will recover faster than premium. We're watching that very carefully, that we saw in the last three weeks of March and April, that being through the trough, and now all indication, number of calls, number of visits, and other things that we are seeing is slowly ramping up. We don't have any specific information that I can share, talk about that balance between premium and value at this point.
Okay, thank you.
Your next question is from Elizabeth Anderson with Evercore.
Hi, guys. Thanks for the commentary. I have a question. In terms of the cost cutting, I understand what you're saying regarding the 2Q cost cutting, but could you provide a few more details in terms of the longer-term cost cutting? Like, what areas are you really focused on, and how do you see that progressing over the course of the year? Thanks.
Sure, Elizabeth, this is Howard. Thanks for the question. When we talk about the $100 million that are more structural in nature, we're looking at, you know, exit a less differentiated, you know, the low growth, low margin product lines that we have, that we will be structurally challenged in. Amir talked about the Pelton & Crane in North America. We think that there are some, you know, potentially some smaller capital businesses, likely, you know, about 1% of our revenue that would also fall into that class. We're looking at reducing footprint by shuttering several facilities. Reducing complexity of the overall organization, span of control would be something that we'd look at as well.
You know, really on the, on the workforce restructuring side, we would target more than 10% of our workforce to go ahead and get to those structural savings as well. I mean, I think.
Okay.
Go ahead.
Sorry, go ahead.
No, I was just going to say that between those activities and then the temporary ones that we talked about, and an additional $100 million, that will be mostly in Q2. I will say that in April, we have seen significant acceleration on cost savings, both in those temporary, as it relates to the furloughs, the compensation reductions, the discretionary spend around travel and events. You know, those would be year-over-year, and the quarter will likely be down 25%, and we're seeing a lot of that accelerated cost savings take hold here in April, as well as some of these more structural things that we just talked about.
Got it. That's very helpful. As part of these cost cutting or sort of changes in your thinking because of this, have you ever given some thought or made any changes to your thinking about how you guys work with distributors?
Elizabeth, our relationship with distributors have not changed at all. We value the relationship and the partnership that we have. We think that they provide value by being available, providing support to dentists, and we intend to continue to work with them as we go forward. One thing that is noticed, that we have seen, is due to some of the challenges in Taiwan, inventories have been the lowest that we have ever seen from the day that we started tracking these. We think that provides opportunity on the recovery aspect process. That gives us an opportunity to manage that a lot better than what we have done. As you well know, we have been at it for the past several years.
Simple answer is, we continue to be dependent and work with them, and, we have every intention of to continue to work with them.
Great! Thank you very much. Your next question is from Nathan Rich with Goldman Sachs.
Hi, Nathan.
Hey, Nate.
Hi, good afternoon. maybe just following up on Elizabeth's question on the cost savings. Howard, I just wanted to, you know, be clear, there's a $100 million assumed additional product rationalization beyond what you talked about with Pelton & Crane. are there, you know, products or categories where you feel, you know, maybe it's a drag on kind of profitability right now, that could be potentially beneficial to exit in this current environment?
Yeah. Nathan, sure. I think that, you know, the $100 million that we talked about structurally, that includes, you know, some of the recent announced actions, including the Pelton & Crane. I think that we would look at other capital areas. I mean, you know, some places in Latin America, potentially, I think that would be also an area that we'd be looking at and analyzing, as well as potential opportunity. The big thing for us is looking at, you know, where do we have products that are highly capital intensive, lower margins, lower growth, and making sure that those are the areas that we scrutinize.
Okay, great. Thanks. Amir, maybe just a follow-up on the implant business. Could you talk about the performance of that business, kind of since you took the restructuring action in 4Q, and kind of what you've seen, you know, three months into that? As we look forward from here, you know, can you kind of talk us through what the priorities are for that business as we move forward?
Of course. Thank you, Nate. As you know, we started making some changes in North America and Western Europe. The sales organization, delayering, getting a lot closer to our customers. The first two months, January and February, North America and Western Europe sales were at high single-digit in our premium business. We saw that traction starting in late January, late December, and I start seeing it in January and February. We had a lot of good feedback from our customers, from the sales force. As this momentum started taking place, we started seeing a little bit of a degradation at beginning of April, and the last three weeks of April really changed the trajectory of this business.
We think that the changes we have done is going to put us in a very different place as we go forward. These changes are going to set us up for the long-term performance of this business. Let me just go back and answer the question on what the priority is. I just want to clarify one thing. I, January and February is mid-single digit growth on the premium in North America and Western Europe. We have three key priorities on that business. We have products, as it stand today, the best-in-class, and feedback that we are getting from our customers continue to say that the product are really meeting the expectation. Commercial execution, getting a lot closer to our customers, providing better customer experience, that is the number one priority.
Number two priority for us, to make sure that the investment that we have made in Nobel, specific in the past four or five years, give us an opportunity to get the new generation of a product around N1, around the new surface, launch properly, expand it properly, and see the benefit of that, so customer can see the benefit of it as we go forward. The third priority for us, as you know, we have talked about portfolio. We have some gap in our portfolio around regenerative, about value, to make sure that we can complete our portfolio gaps. Those priorities have not changed. We started with the commercial activities in Q3 and Q4. N1, we gave you a status update and continue to be an important part of the innovation moving forward.
As, hopefully, the commodities crisis will be in a far better place to accelerate a portfolio management, adding to our portfolio to make sure that we can meet the requirement of our customers worldwide.
Good. Thank you.
Your next question is from Jonathan Block with Stifel.
Thanks. Good afternoon, guys. Amir, in terms of the trajectory of the market coming back, I'm just curious what you're hearing, you know, in your conversations regarding hygiene. That's seemingly lagging due to the concerns with aerosols that you hear out there. You know, what are you hearing? What does that mean for restorative procedures down the road, as hygiene usually acts as a leading indicator for restorative? Could that actually sort of be maybe a pocket, you know, once we get into the fall time frame, if hygiene doesn't resume shortly, and then I've got a follow-up. Thanks.
What we are hearing is that the high-speed, as well as procedures that have create more of a damage, for lack of better description, to the tissues and bone, are the one that have a little bit more of a concern. That's why there is a, you know, in some categories, there are lower risk, lower transmission risk to restorative, to hygiene, to endo, and there are additional clinical benefits as well, that could be used as a replacement. For example, lower risk versus other procedure using a high-speed handpiece, or ultrasonic scaler. Lower speed drill, 1,000 or 2,000 RPM versus 200,000 RPM that normally use in resto.
Normally, when you look at the implant as an example, in most cases, you go to an environment that it is really sterilized, advanced sterilization, surgical suits, that already existed before any of these. We think some of those would have a really impact in some procedures coming back a lot faster than others. John, upon saying that, we have been seriously looking at product categories that have a better performance, better trajectory, and we are lining up very quickly, very fast around those, on those categories to make sure that we are prepared as the market comes back, that we can see the benefit that's back.
Got it. Okay, great. Just to pivot to the second question, you know, Spark, I know it's early, but you did mention it contributed 50 basis points to revenue growth. Where are those sales coming from? I assume they're Ormco, has their underlying wires and brackets growth remained intact, so you can tell, you know, if those sales are truly incremental, and how are they using it, on the adults, on the teens? Just any early feedback would be great. Thanks, guys.
Yeah, great. Of course, John. The first two months of the year, Ormco, traditional bracket and wire, continued to operate in the same format that it has done in the past, mid-single digit. During 2019, we saw exactly the same thing. Our traditional bracket and wire business continues to operate at a mid-single digit growth, while the market is 0%-1%. While we have introduced the Spark, that really hasn't taken anything away from our traditional bracket and wire. We introduced the Spark, as we have talked about before, to our traditional Ormco business customers. Those customers, they know us, they have a good relationship with us, and what they have done is basically offer different set of alternatives, that they can use either bracket and wire, the Spark, or a combination of the both. They are using it in many of the cases.
You know, the number of customers that they're using today, we have a finite, we know exactly who they are, they're providing input to us, and they have told us that they can treat almost all indication in all cases using the Spark. Where they came from, exactly as what we had expected. China started ramping up pretty quickly in January. US continued to be the next phase, got signed up, and then we had a very early introduction in Europe, and Australia and New Zealand continued to get send us cases. What we expected in Q1 is exactly what we received, despite the fact that we had some challenges in March. What we are beginning to see similar trajectory as we saw in January and February.
Areas that we have introduced the product, where we have gone through this phased, disciplined approach of training, education, customer support, change of the processes, are we beginning to see that coming back? We are ramping up, as we said before, production, to be able to make sure that we are in a good place answering the demand this year.
Great. Very helpful. Thank you.
Your next question is from Brandon Couillard with Jefferies.
Amir, just back on N1. What's the distinction of, you described the CE mark being the first portfolio launch? Just curious what the distinction is there, and do you have an updated timeline for US submission, to the FDA?
Right. N1 is a complete system, Brandon. It's a system of the drill unit, the implant itself, the conical connection that goes on top of it, the surgical units, the packaging, all of that, step by step by step, is coming through. Right now, the most important part, which was basically having that implant being approved, it has been approved. We're going to start selling that implant, and we have been building inventory in order for us to be able to go to those countries that they don't require any additional registration. I think about 12 to 14 countries in Europe, we're going to start selling that immediately, and the others that require registration, is a very short registration process. Really pleased with what is taking place.
N1 is a series of innovation that comes one after another. Phase two would be coming after that, and we continue to expand on it as we go forward. FDA discussion is underway. We're in back and forth on pre-submission dialogue and getting advice from consultants and people who really know the industry very well, to make sure that we are in a good place as we go forward. I cannot provide any specific timeline. I'll go all along. As we have indicated in the past, Europe end of this year and United States in 2021, later in 2021. The European approval obviously bring that forward, but I don't think that has, if we have any additional information or that we can share at this point about the US FDA approval.
Thanks. Just one question to follow up, for Howard, maybe in terms of the $100 million structural cost savings. You know, can you break that down in terms of where in P&L, that will manifest, and to what extent the sales force, you know, might be impacted in certain parts of the business from the headcount reduction? Thanks.
Yeah. Brandon, I don't think that, you know, the structural changes, we've done some of those in the sales force around the Nobel piece last year in December, as we spoke about. We don't anticipate a lot of impact as it relates to the sales organizations and feet on the street for us. What we do anticipate is that we'll have more structural changes around facilities, back office as well, shared service functions, as well as, you know, looking at these things like Pelton & Crane, which we just announced, which will obviously have some manufacturing footprint changes as well. I think it's going to be throughout the P&L, largely in the G&A components versus the selling component.
We will also have some impact on the cost of sales or the manufacturing lines as well.
Very good. Thank you.
Yep.
That ends our allotted time for questions and answers to management. I'll turn the call back over to you for any closing remarks.
Thank you, Erica, and everybody, we'll be around for follow-ups today, tomorrow, rest of the week. Thank you everyone for joining us.
Thank you.
Thank you.
Ladies and gentlemen, this concludes today's conference call. Thank you for participating. You may now disconnect.